KRAS and non-small cell lung carcinoma: Phosphatidylinositol 3-kinase (PIK3CA) mutations frequently co-exist with EGFR or KRAS mutations in NSCLC and suggest poor prognosis in the EGFR/KRAS subgroup [23].